Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 04 June 2014 | By Alexander Gaffney, RAC,
European regulatory officials have tightened the standards for obtaining approval for a drug name, reducing the number of proposed names companies can put forth for consideration at any one time.
The change, contained in a revised guideline, on the Acceptability of Names for Human Medicinal Products Processed Through the Centralised Procedure, reduces the number of proposed names that may be sent to the European Medicines Agency (EMA) to two invented names.
At present, companies can submit as many as four names at each Name Review Group (NRG) meeting. In the future, companies will only be able to submit two at any one meeting. If both names are rejected, the company will need to propose up to two new names in a subsequent meeting of the NRG.
EMA said in a statement that the change will not be retroactive, giving companies until 1 January 2015—the implementation date for the guideline—to submit proposed names without penalty.
The NRG will also, in rare cases, be able to make exceptions for companies to submit more than two names, EMA said. Contributing factors might include:
In such cases, the marketing authorization holder will need to then indicate which two invented names should be maintained in the marketing authorization application, EMA wrote.
EMA also wrote that the MAHs should "clearly indicate at the time of submission whether the proposed (invented) names are intended to be used in the context of multiple marketing-authorisation applications. This is to allow the NRG to review whether the proposed (invented) names are not potentially confusing with each other."
EMA Guideline
EMA Statement
Tags: Labeling, Invented Name, Proprietary Name, INN
Regulatory Focus newsletters
All the biggest regulatory news and happenings.